Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Summary
This is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK),Pharmacodynamic characteristics, immunogenicity and antitumor activity of JS207 in patients with advanced malignant tumor. The Recommended dose for phase II trial (RP2D) will be determined based on the safety, tolerability, pharmacokinetics.
Official title: A Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
98
Start Date
2023-09-26
Completion Date
2026-06-30
Last Updated
2025-09-18
Healthy Volunteers
No
Conditions
Interventions
JS207
Patients will receive specific dose of JS207 via intravenous infusion.
Locations (1)
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China